KOVERA LABS · CLIENT RECORD·SNAPSHOT 2026-08-02
Zyron Research: 13 Kovera certificates.
The lab's record shows 13 certificates printed for Zyron Research, analysed between 27 Feb 2026 and 2 Apr 2026, covering 11 products. Median HPLC purity is 99.94%. Kovera graded 13 as a pass and 0 as a fail.
13
certificates
99.94%
median purity
11
products
0
lab verdict: fail
1
failure rules met
What the record shows
RETRIEVED 2 AUGUST 20261 of the 13 certificates meet at least one of our failure rules. They are shaded in the table below. 9 measured more than 110% of the label, which Kovera does not grade as a fail.
A certificate covers the sample the client sent, and the client decides which results go public. The figures are as published on 2 August 2026; check the lab's verify page for the current version before you rely on one.
Products tested
11 AS PRINTEDRetatrutide · 2Tirzepatide · 2BPC-157/TB-500 · 1CJC-1295 (No DAC)/Ipamorelin · 1GHK-Cu · 1Klow · 1KPV · 1MOTS-c · 1N-Acetyl Semax Amidate · 1NAD+ · 1ZR-TZ · 1
Every certificate
NEWEST FIRST · 13 ROWS| Report | Product | Lot | Purity | % of label | Analysed | Result | Check |
|---|---|---|---|---|---|---|---|
| KVR-2026-F7C075 | N-Acetyl Semax Amidate | ZR-SMX10-B0326-1 | 99.959% | 113.1%11.31 of 10 mg | 2 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-D66AAD | ZR-TZ | ZR-TZ40-B0326-1 | 99.963% | 107.0%42.81 of 40 mg | 2 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-7D74F8 | CJC-1295 (No DAC)/Ipamorelin | ZR-CJCIPA5-B0326-1 | 99.846% | 109.0%10.9 of 10 mg | 2 Apr 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-345C28 | BPC-157/TB-500 | ZR-BPCTB10-B0326-1 | 99.76% | 115.1%11.51 of 10 mg | 2 Apr 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-AD00D9 | MOTS-c | ZR-MOTS10-B0326-1 | 99.927% | 106.4%10.64 of 10 mg | 20 Mar 2026 | PASS | Kovera ↗our verifier → |
| KVR-2026-52D50F | KPV | ZR-KPV10-B0326-1 | 99.942% | 118.4%11.84 of 10 mg | 20 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-1CF80C | GHK-Cu | ZR-GHK100-B0326-1 | 99.948% | 117.0%116.98 of 100 mg | 20 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-E6BE5E | Retatrutide | ZR-RT15-B0326-1 | 99.944% | 115.7%17.36 of 15 mg | 19 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-179F0C | Tirzepatide | ZR-TZ15-B0326-1 | 99.962% | 117.6%17.64 of 15 mg | 19 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-E62B0D | Tirzepatide | ZR-TZ30-B0326-1 | 99.973% | 115.0%34.51 of 30 mg | 3 Mar 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-B9B935 | NAD+ | ZR-NAD-B0326-1 | 99.716% | 82.6%412.84 of 500 mg | 27 Feb 2026 | PASSunder 90% of label | Kovera ↗our verifier → |
| KVR-2026-9320E6 | Klow | ZR-KLOW-B0326-1 | 99.812% | 110.0%88.04 of 80 mg | 27 Feb 2026 | PASSover 110% of label | Kovera ↗our verifier → |
| KVR-2026-085825 | Retatrutide | ZR-RT30-B0326-1 | 99.916% | 114.7%34.41 of 30 mg | 27 Feb 2026 | PASSover 110% of label | Kovera ↗our verifier → |